CR Intrinsic Investors’s Medtronic MDT Stock Holding History

CR Intrinsic Investors’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-50,000	Closed	-$3.08M	–	117
2014 Q1	$3.08M	Sell	50,000 -125,000	-71%	-$7.28M	0.12%	213
2013 Q4	$10M	Buy	175,000 +75,000	+75%	+$4.25M	0.44%	78
2013 Q3	$5.33M	Buy	+100,000	New	+$5.38M	0.16%	180

Other funds holding MDT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

CR Intrinsic Investors's MDT Position: Q2 2014 in Review

CR Intrinsic Investors sold out of Medtronic (MDT) in Q2 2014, closing a stake of 50,000 shares — an estimated $3.08M sold.

CR Intrinsic Investors first reported a position in MDT in Q3 2013 and held it in 3 quarters. The position peaked at $10M in Q4 2013. 1,110 funds tracked by Wall St. Rank hold MDT as of Q2 2014.

CR Intrinsic Investors reported no remaining Medtronic position as of Q2 2014 after selling out during the quarter.
CR Intrinsic Investors sold 50,000 Medtronic shares in Q2 2014, an estimated $3.08M.
CR Intrinsic Investors first reported a position in Medtronic in Q3 2013 and held it in 3 quarters.
CR Intrinsic Investors's Medtronic position peaked at $10M in Q4 2013.
1,110 funds tracked by Wall St. Rank held Medtronic as of Q2 2014.

Based on CR Intrinsic Investors's 13F filing for Q2 2014.